| |
| |
|
| Insider
Information: |
Topper James N |
| Relationship: |
|
| City: |
Seattle |
| State: |
WA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
14 |
|
| Direct
Shares |
20,705,444 |
|
|
Indirect Shares
|
36,606,767 |
|
|
| Direct
Value |
$202,318,919 |
|
|
|
Indirect Value
|
$701,397,711 |
|
|
| Total
Shares |
57,312,211 |
|
|
| Total
Value |
$903,716,629 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
3
|
1
|
|
Stock
price went up :
|
0
|
1
|
| Stock
price went down : |
3
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
-3.0
|
1.0
|
| Percentage
Gain/Loss : |
 -17.1%
|
 0.3%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
La Jolla Pharmaceutical Co |
LJPC |
Director |
2005-12-14 |
0 |
2009-02-26 |
0 |
Premium* |
|
|
Amicus Therapeutics Inc |
FOLD |
Director, 10% Owner |
2007-06-05 |
0 |
2008-03-10 |
3,520,678 |
Premium* |
|
|
Portola Pharmaceuticals Inc |
PTLA |
Director |
2013-05-28 |
0 |
2013-05-28 |
1,428,954 |
Premium* |
|
|
Sierra Oncology Inc |
SRRA |
Director, 10% Owner |
2015-07-21 |
0 |
2017-02-14 |
8,112,121 |
Premium* |
|
|
Anaptysbio Inc |
ANAB |
Director |
2020-11-16 |
80,812 |
2020-11-16 |
199,529 |
Premium* |
|
|
Alpine Immune Sciences Inc |
ALPN |
|
2022-02-11 |
1,484,115 |
2024-04-25 |
2,829,347 |
Premium* |
|
|
Allena Pharmaceuticals, Inc. |
ALNA |
Director, 10% Owner |
2017-11-06 |
0 |
2017-11-06 |
3,330,373 |
Premium* |
|
|
Aptinyx Inc. |
APTX |
Director |
2018-06-25 |
0 |
2020-03-31 |
3,195,055 |
Premium* |
|
|
Entasis Therapeutics Holdings Inc. |
ETTX |
Director, 10% Owner |
2018-09-28 |
0 |
2018-09-28 |
1,349,953 |
Premium* |
|
|
Mirum Pharmaceuticals, Inc. |
MIRM |
10% Owner |
2019-07-22 |
3,566,912 |
2019-07-22 |
0 |
Premium* |
|
|
Arcutis Biotherapeutics, Inc. |
ARQT |
10% Owner |
2020-02-04 |
10,542,790 |
|
0 |
Premium* |
|
|
Passage Bio, Inc. |
PASG |
10% Owner |
2020-03-03 |
5,009,219 |
2020-03-03 |
0 |
Premium* |
|
|
Phathom Pharmaceuticals, Inc. |
PHAT |
Director, 10% Owner |
2023-05-25 |
21,596 |
2023-05-25 |
5,831,328 |
Premium* |
|
|
Newamsterdam Pharma Ord Shs |
NAMS |
|
|
0 |
2024-03-26 |
6,809,429 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
93 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ARQT |
Arcutis Biotherapeutics, ... |
10% Owner |
– – • |
2020-01-30 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
509,032 |
|
- |
|
| NAMS |
Newamsterdam Pharma Ord S... |
|
– • – |
2023-12-29 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
6,801,000 |
|
- |
|
| ALPN |
Alpine Immune Sciences In... |
|
– • – |
2024-04-25 |
4 |
S |
$64.57 |
$1,227 |
I/I |
(19) |
2,829,347 |
0 |
% |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2008-02-22 |
4 |
B |
$10.09 |
$2,019 |
I/I |
200 |
709,981 |
2.17 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2008-03-10 |
4 |
B |
$9.98 |
$7,651 |
I/I |
760 |
915,924 |
2.17 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2008-02-26 |
4 |
B |
$9.99 |
$19,323 |
I/I |
1,900 |
727,681 |
2.17 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2008-02-22 |
4 |
B |
$9.53 |
$19,197 |
I/I |
2,000 |
703,167 |
2.17 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2008-02-28 |
4 |
B |
$9.84 |
$20,195 |
I/I |
2,038 |
753,019 |
2.17 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2007-07-26 |
4 |
B |
$11.19 |
$44,083 |
I/I |
3,896 |
200,911 |
2.25 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2007-07-26 |
4 |
B |
$11.44 |
$47,160 |
I/I |
4,104 |
205,015 |
2.25 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2007-06-28 |
4 |
B |
$11.48 |
$49,201 |
I/I |
4,281 |
153,415 |
2.25 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2008-03-04 |
4 |
B |
$9.60 |
$43,719 |
I/I |
4,500 |
834,018 |
2.25 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2007-06-28 |
4 |
B |
$11.32 |
$53,954 |
I/I |
4,734 |
149,134 |
2.25 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2008-03-10 |
4 |
B |
$10.19 |
$48,696 |
I/I |
4,740 |
920,664 |
2.25 |
- |
|
| APTX |
Aptinyx Inc. |
Director |
– • – |
2020-03-31 |
4 |
A |
$2.16 |
$10,748 |
I/I |
4,976 |
3,195,055 |
0 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2008-02-21 |
4 |
B |
$9.86 |
$56,254 |
I/I |
5,500 |
701,167 |
2.25 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2008-02-01 |
4 |
B |
$9.01 |
$50,729 |
I/I |
5,600 |
295,915 |
2.25 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2008-02-11 |
4 |
B |
$9.93 |
$57,274 |
I/I |
5,700 |
608,267 |
2.25 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2008-02-28 |
4 |
B |
$9.97 |
$58,068 |
I/I |
5,762 |
758,781 |
2.25 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2008-02-13 |
4 |
B |
$10.44 |
$60,799 |
I/I |
5,800 |
629,667 |
2.25 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2008-02-26 |
4 |
B |
$9.49 |
$59,252 |
I/I |
6,100 |
725,781 |
2.25 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2008-02-13 |
4 |
B |
$10.10 |
$64,025 |
I/I |
6,200 |
623,867 |
2.25 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2008-01-31 |
4 |
B |
$9.38 |
$60,020 |
I/I |
6,215 |
258,630 |
2.25 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2008-02-22 |
4 |
B |
$9.67 |
$65,218 |
I/I |
6,614 |
709,781 |
2.25 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2008-02-15 |
4 |
B |
$10.47 |
$72,439 |
I/I |
6,900 |
636,567 |
2.25 |
- |
|
93 Records found
|
|
Page 1 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
